- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Integrating Momelotinib: NCCN Guidelines and Drug Comparison
Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Gerds discusses the integration of momelotinib into NCCN guidelines following the FDA’s approval in September 2023 based on results from the MOMENTUM trial (NCT04173494). He acknowledges the swift inclusion of momelotinib while emphasizing ongoing efforts for a comprehensive guideline renovation. Gerds sheds light on the differentiation of JAK inhibitors, considering adverse effects, patient characteristics, and treatment goals. He provides a simplified approach, categorizing patients based on platelet counts and anemia status to guide JAK inhibitor selection. The discussion extends to addressing potential treatment-related anemia and the complexity of distinguishing disease-related factors. Gerds underscores the importance of understanding individual patient profiles, historical data, and inflammatory markers when devising strategies to manage anemia effectively. The segment highlights the meticulous and responsive nature of NCCN guidelines, ensuring clinicians have updated and tailored recommendations for myelofibrosis treatment.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
DMD Guidance Could Benefit From Update, Experts Say
January 24th 2024MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
July 7th 2023Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for DLBCL
June 23rd 2023Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.
Read More
Review Finds EORTC QLQ-MY20 Useful, Robust 25 Years After Development
June 16th 2023The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.
Read More
ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC
April 27th 2023The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).
Read More
